R_3 is hydrogen, (C_1-C_4) alkyl, (C_1-C_4) substituted alkyl, (C_1-C_4) alkyl substituted with one or more fluorine atoms; arylalkyl or substituted arylalkyl;

R_4 and R_5 are independently hydrogen, (C_1-C_4) alkyl, substituted (C_1-C_4) alkyl, (C_1-C_4) alkyl substituted with one or more fluorine atoms, heteroalkyl, substituted hetereoalkyl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl;

R_{11} is hydrogen, (C_1-C_3) alkyl or (C_1-C_3) alkyl substituted with one or more fluorine atoms;

R_{12} is hydrogen, alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted hetereoalkyl, substituted heteroarylalkyl or $-S(O)_mR_{108}$;

R_{100}-R_{108} are independently hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted hetereoalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;

m and k are independently 0, 1 or 2; and

n is 0, 1, 2 or 3;

provided that at least one of R_4 or R_5 is substituted with fluorine.

In a second aspect, there is provided a composition comprising the compound as disclosed herein and a vehicle.

In a third aspect, there is provided the use of a therapeutically effective amount of the compound as disclosed herein in the manufacture of a medicament for treating and/or preventing migraine.

In a fourth aspect, there is provided the use of a therapeutically effective amount of the composition as disclosed herein in the manufacture of a medicament for treating and/or preventing migraine.

In a fifth aspect, there is provided the use of a therapeutically effective amount of the compound as disclosed herein in the manufacture of a medicament for treating and/or preventing one or more symptoms of Parkinson's disease.

In a sixth aspect, there is provided the use of a therapeutically effective amount of the composition as disclosed herein in the manufacture of a medicament for treating and/or preventing one or more symptoms of Parkinson's disease.

In a seventh aspect, there is provided the use of a therapeutically effective amount of the compound as disclosed herein in the manufacture of a medicament for agonizing the D_2 receptor.

In an eighth aspect, there is provided the use of a therapeutically effective amount of the compound as disclosed herein in the manufacture of a medicament for agonizing the 5-HT_{1D} receptor.



In a ninth aspect, there is provided the use of a therapeutically effective amount of the compound as disclosed herein in the manufacture of a medicament for selectively agonizing the 5-HT_{1D} receptor over the 5-HT_{1B} receptor.

In a tenth aspect, there is provided the use of a therapeutically effective amount of the compound as disclosed herein in the manufacture of a medicament for providing functional antagonist activity at the 5-HT_{2B} receptor.



Also provided are derivatives, including salts, esters, enol ethers, enol esters, solvates, hydrates and prodrugs of the compounds described herein. Further provided are compositions which include the compounds provided herein and a vehicle.

Methods of treating, preventing, or ameliorating symptoms of medical disorders such as, for example, migraine, ALS, Parkinson's disease, extra-pyramidal disorders, depression, nausea, restless legs syndrome, insomnia, aggression, Huntington's disease, dystonia, parsomnia and hyperlactinemia are also provided herein. In practicing the methods, therapeutically effective amounts of the compounds or compositions thereof are administered to a subject.

Methods of antagonizing receptors such as, for example 5-HT_{2B}, adrenergic receptors suchas, for example, $alpha_{1A}$, $alpha_{1D}$, $alpha_{2A}$, $alpha_{2B}$ and $alpha_{2C}$ with the compounds and compositions described herein are also provided herein. Methods of agonizing dopaminergic D2 receptors and/or antagonizing or

6. The compound of 1 having the structure:

7. A composition comprising the compound of Claim 1 and a vehicle.

8. ~~A method of treating and/or preventing migraine in a subject comprising administering to the subject in need thereof~~Use of a therapeutically effective amount of the compound of Claim 1 in the manufacture of a medicament for treating and/or preventing migraine.

9. ~~A method of treating and/or preventing migraine in a subject comprising administering to the subject in need thereof~~Use of a therapeutically effective amount of the composition of Claim 7 in the manufacture of a medicament for treating and/or preventing migraine.

10. ~~A method of treating and/or preventing one or more symptoms of Parkinson's disease in a subject comprising administering to the subject in need thereof~~Use of a therapeutically effective amount of the compound of Claim 1 in the manufacture of a medicament for treating and/or preventing one or more symptoms of Parkinson's disease.

11. ~~A method of treating and/or preventing one or more symptoms of Parkinson's disease in a subject comprising administering to the subject in need thereof~~ Use of a therapeutically effective amount of the composition of Claim 7 in the manufacture of a medicament for treating and/or preventing one or more symptoms of Parkinson's disease.

12. ~~A method of agonizing the D_2 receptor in a subject comprising administering to the subject in need thereof~~Use of a therapeutically effective amount of the compound of Claim 1 in the manufacture of a medicament for agonizing the D_2 receptor.

13. ~~A method of agonizing the 5-HT_{1D} receptor in a subject comprising administering to the subject in need thereof~~Use of a therapeutically effective amount of the compound of Claim 1 in the manufacture of a medicament for agonizing the 5-HT_{1D} receptor.

14. ~~A method of selectively agonizing the 5-HT_{1D} receptor over the 5-HT_{1B} receptor in a subject comprising administering to the subject in need thereof~~Use of a therapeutically effective amount of the compound of Claim 1 in the manufacture of a medicament for selectively agonizing the 5-HT_{1D} receptor over the 5-HT_{1B} receptor.

15. ~~A method of providing functional antagonist activity at the 5-HT_{2B} receptor in a subject comprising administering to the subject in need thereof~~ Use of a therapeutically effective amount of the compound of Claim 1 in the manufacture of a medicament for providing functional antagonist activity at the 5-HT_{2B} receptor.